drugset / Trial / NCT00128583

Vaccine Therapy in Treating Patients With Malignant Melanoma

NCT00128583 ↗

Phase 2 Unknown CancerVax Corporation
Open-labelTreatment

Summary

RATIONALE: Vaccines made from tumor cells may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase II trial is studying vaccine therapy to see how well it works in treating patients with malignant melanoma.

Timeline

Start
2005-07
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Canvaxin Vaccine — Subcutaneous

Indications